New CAR-T therapy aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07093073
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will enroll 30 participants to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- U01 (ssCART-19) CAR-T cells
- What this could lead to
- If successful, this could offer a new treatment option for patients with B-cell lymphoma that has not responded to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people, so it may not work for everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital of Tongji University
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?
- Military study probes Toxins' role in lymphoma
- Off-the-Shelf immune cells take on tough lymphoma